ICPO and WFNMB Forge Global Alliance to Scale Precision Theranostics

The global oncology landscape is witnessing a paradigm shift toward precision medicine, and the recent cooperation agreement between the ICPO Foundation and the World Federation of Nuclear Medicine and Biology (WFNMB) marks a significant milestone in this evolution. By aligning the ICPO’s focus on infrastructure and education with the WFNMB’s vast global network of nuclear medicine societies, the partnership aims to accelerate the adoption of Theranostics—a dual-purpose approach that combines diagnostic imaging with targeted radiopharmaceutical therapy. This development comes at a time when the demand for targeted cancer treatments is outstripping the available clinical capacity, particularly in emerging markets.

Theranostics has transitioned from a niche academic interest to a multi-billion dollar market, driven by the success of agents like Pluvicto for prostate cancer and Lutathera for neuroendocrine tumors. However, the primary bottleneck for the industry is no longer just drug development, but the lack of standardized clinical protocols and a shortage of qualified personnel to administer these complex treatments. The ICPO-WFNMB alliance specifically targets these structural deficiencies. By leveraging the ICPO Academy’s standardized curriculum, the partnership seeks to create a global workforce capable of operating high-tech precision oncology centers, ensuring that the 'bench-to-bedside' pipeline is not restricted by geographical or educational barriers.

“

Theranostics has transitioned from a niche academic interest to a multi-billion dollar market, driven by the success of agents like Pluvicto for prostate cancer and Lutathera for neuroendocrine tumors.

From a market perspective, this partnership signals a maturing of the radiopharmaceutical sector. Investors and pharmaceutical giants, including Novartis, Eli Lilly, and Bristol Myers Squibb, have spent billions acquiring radioligand therapy platforms. For these investments to yield returns, the global healthcare infrastructure must be capable of delivering these therapies safely and effectively. The involvement of the WFNMB, which represents over 80 national societies, provides the necessary institutional weight to influence regulatory standards and reimbursement policies across different jurisdictions. This institutional alignment is crucial for creating a predictable environment for further capital investment in the sector.